SG170752A1 - Benzimidazoles which have activity at m1 receptor and their uses in medicine - Google Patents

Benzimidazoles which have activity at m1 receptor and their uses in medicine

Info

Publication number
SG170752A1
SG170752A1 SG201102019-5A SG2011020195A SG170752A1 SG 170752 A1 SG170752 A1 SG 170752A1 SG 2011020195 A SG2011020195 A SG 2011020195A SG 170752 A1 SG170752 A1 SG 170752A1
Authority
SG
Singapore
Prior art keywords
benzimidazoles
receptor
medicine
activity
compounds
Prior art date
Application number
SG201102019-5A
Other languages
English (en)
Inventor
David Gwyn Cooper
Ian Thomson Forbes
Vincenzo Garzya
Jian Jin
Yann Louchart
Graham Walker
Paul Adrian Wyman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SG170752A1 publication Critical patent/SG170752A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG201102019-5A 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine SG170752A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0605786.3A GB0605786D0 (en) 2006-03-22 2006-03-22 Compounds

Publications (1)

Publication Number Publication Date
SG170752A1 true SG170752A1 (en) 2011-05-30

Family

ID=36383995

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201102019-5A SG170752A1 (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine

Country Status (22)

Country Link
US (3) US20100280071A1 (xx)
EP (1) EP2004182B1 (xx)
JP (1) JP5256187B2 (xx)
KR (1) KR20090015027A (xx)
CN (2) CN101448495B (xx)
AR (1) AR059977A1 (xx)
AU (1) AU2007228716A1 (xx)
BR (1) BRPI0708999A2 (xx)
CA (1) CA2646896A1 (xx)
CR (1) CR10314A (xx)
EA (1) EA200870360A1 (xx)
GB (1) GB0605786D0 (xx)
IL (1) IL194206A0 (xx)
MA (1) MA30324B1 (xx)
MX (1) MX2008012160A (xx)
NO (1) NO20084048L (xx)
NZ (1) NZ595738A (xx)
PE (1) PE20080007A1 (xx)
SG (1) SG170752A1 (xx)
TW (1) TW200813004A (xx)
WO (1) WO2007107565A1 (xx)
ZA (1) ZA200807616B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706187D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
EP2194983A1 (en) * 2007-09-20 2010-06-16 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
US8278328B2 (en) 2007-09-20 2012-10-02 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
WO2009124883A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel 1,3-dihydro-benzoimidazol-2-ones as m1 agonists
GB0817982D0 (en) * 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
JP5990980B2 (ja) * 2012-04-02 2016-09-14 大日本印刷株式会社 オランザピンの中間体の製造方法
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017106328A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
SI3393468T1 (sl) 2015-12-22 2023-01-31 X4 Pharmaceuticals, Inc. Postopki za zdravljenje bolezni imunske pomanjkljivosti
CN107129439A (zh) * 2016-02-26 2017-09-05 中国科学院大连化学物理研究所 一种化合物、毒蕈碱m受体拮抗剂、组合物及应用
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
WO2017223229A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN113637001A (zh) * 2021-08-09 2021-11-12 安康市农业科学研究院 一种氟哌利多中间体的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4040300A1 (de) * 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
AU7478396A (en) * 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine agonists
JPH10330377A (ja) * 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
JP3342478B2 (ja) * 1998-01-19 2002-11-11 ファイザー製薬株式会社 Ｏｒｌ１−レセプターアゴニストとしての４−（２−ケト−１−ベンズイミダゾリニル）ピペリジン化合物
AU1816901A (en) * 1999-12-06 2001-06-12 Euro-Celtique S.A. Benzimidazole compounds having nociceptin receptor affinity
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
JP2005532361A (ja) * 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
RU2005118407A (ru) * 2002-12-13 2006-03-10 СмитКлайн Бичем Корпорейшн (US) Производные пиперидина в качестве антагонистов ccr5
EP1937670A1 (en) * 2005-09-30 2008-07-02 Glaxo Group Limited Benzimidazolones which have activity at m1 receptor

Also Published As

Publication number Publication date
IL194206A0 (en) 2009-08-03
JP2009530347A (ja) 2009-08-27
NO20084048L (no) 2008-10-20
NZ595738A (en) 2012-11-30
CN101448495A (zh) 2009-06-03
PE20080007A1 (es) 2008-03-16
KR20090015027A (ko) 2009-02-11
CN103058990A (zh) 2013-04-24
EP2004182B1 (en) 2013-05-08
US20120041028A1 (en) 2012-02-16
EA200870360A1 (ru) 2009-02-27
MA30324B1 (fr) 2009-04-01
ZA200807616B (en) 2010-07-28
TW200813004A (en) 2008-03-16
AU2007228716A1 (en) 2007-09-27
GB0605786D0 (en) 2006-05-03
CR10314A (es) 2008-12-01
JP5256187B2 (ja) 2013-08-07
US20100280071A1 (en) 2010-11-04
MX2008012160A (es) 2008-10-03
AR059977A1 (es) 2008-05-14
BRPI0708999A2 (pt) 2011-06-21
WO2007107565A1 (en) 2007-09-27
EP2004182A1 (en) 2008-12-24
CN101448495B (zh) 2013-05-08
CA2646896A1 (en) 2007-09-27
US20120316202A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
SG170752A1 (en) Benzimidazoles which have activity at m1 receptor and their uses in medicine
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
UA101299C2 (uk) Сполуки, що мають активність стосовно рецепторів м1, та їх застосування в медицині
IN2014KN02886A (xx)
GB2471588A (en) Therapeutic peptidomimetic macrocycles
EA017278B9 (ru) Соединения азаиндазола и способы применения
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
NO20081844L (no) Terapeutiske forbindelser
RS20090208A (xx) Pirazolin jedinjenja kao antagonisti mineralokortikoid receptora
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
BRPI0813993A2 (pt) Ciclopentanos de pirimidila como inibidores de proteína quinase akt
SG152237A1 (en) Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
EP2155203A4 (en) AZAINDAZOLE COMPOUNDS AND METHODS OF USE
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
MX2011006843A (es) Dihidropiridona-amidas como moduladores de p2x7.
WO2008119720A8 (en) 1-(1-cyclobutyl-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
MX2008001428A (es) Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
IL177169A (en) Use of n-(2-aryl- propionyl)-sulfonamides for the preparation of medicaments for the treatment of spinal cord injury
MX2010001303A (es) Compuestos terapeuticos.
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
MX2010004314A (es) Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso.
SG149051A1 (en) Nicotinic acetylcholine receptor ligands